. Kinetic analysis and comparison of uptake, distribution, and excretion of 48 V-labeled compounds in rats. J. Appl. Physiol. 84(2): 569-575, 1998.-Vanadium has been found to be orally active in lowering plasma glucose levels; thus it provides a potential treatment for diabetes mellitus. Bis(maltolato)oxovanadium(IV) (BMOV) is a well-characterized organovanadium compound that has been shown in preliminary studies to have a potentially useful absorption profile. Tissue distributions of BMOV compared with those of vanadyl sulfate (VS) were studied in Wistar rats by using 48 V as a tracer. In this study, the compounds were administered in carrier-added forms by either oral gavage or intraperitoneal injection. Data analyzed by a compartmental model, by using simulation, analysis, and modeling (i.e., SAAM II) software, showed a pattern of increased tissue uptake with use of 48 V-BMOV compared with 48 VS. The highest 48 V concentrations at 24 h after gavage were in bone, followed by kidney and liver. Most ingested 48 V was eliminated unabsorbed by fecal excretion. On average, 48 V concentrations in bone, kidney, and liver 24 h after oral administration of 48 V-BMOV were two to three times higher than those of 48 VS, which is consistent with the increased glucose-lowering potency of BMOV in acute glucose lowering compared with VS. vanadium; compartmental modeling; simulation, analysis, and modeling software; diabetes; insulin mimetic DESPITE ITS UBIQUITOUS PRESENCE in mammalian tissues (26), vanadium is an ultratrace element, the essentiality of which has not yet been conclusively demonstrated. Homeostatic mechanisms ensure low levels of absorption of dietary vanadium (30) 3Ϫ and/or VO 2ϩ has been shown to increase glucose uptake and to stimulate glycogen synthesis in rat diaphragm, liver, and fat cells (39), to enhance glucose transport and oxidation in rat adipocytes and skeletal muscle (9, 15, 34) , and to inhibit lipolysis (16) and activate lipogenesis (36) in rat adipocytes.
DESPITE ITS UBIQUITOUS PRESENCE in mammalian tissues
, vanadium is an ultratrace element, the essentiality of which has not yet been conclusively demonstrated. Homeostatic mechanisms ensure low levels of absorption of dietary vanadium (30) and rapid clearance of vanadium from the bloodstream (31) . Numerous studies have demonstrated the insulin-mimetic actions of vanadium both in vitro and in vivo (for reviews, see Refs. 27, 29, and 35) . The most common physiologically relevant ions of vanadium are vanadate [VO 4 3Ϫ ; V(V)] and vanadyl [VO 2ϩ ; V(IV)] (8). In vitro, VO 4 3Ϫ and/or VO 2ϩ has been shown to increase glucose uptake and to stimulate glycogen synthesis in rat diaphragm, liver, and fat cells (39) , to enhance glucose transport and oxidation in rat adipocytes and skeletal muscle (9, 15, 34) , and to inhibit lipolysis (16) and activate lipogenesis (36) in rat adipocytes.
A key advantage of vanadium over insulin is its effectiveness when administered orally (20) . Unfortunately, poor absorption from the gastrointestinal (GI) tract into the blood, coupled with doses close to toxic levels for glucose-and lipid-lowering effects, has hampered efforts to develop vanadium compounds as therapeutic adjuncts for treatment of diabetes mellitus (19, 29, 33) . Although both VO 2ϩ (10) and VO 4 3Ϫ (17) have recently shown positive results in limited clinical trials in humans, the search is underway for better absorbed and less toxic vanadium compounds (27) .
One such compound that has been synthesized in our laboratories and has undergone extensive testing over the last several years is bis(maltolato)oxovanadium(IV) (BMOV) ( Fig. 1) (25) . BMOV can be readily synthesized (7) by combining vanadyl sulfate (VS) and maltol (3-hydroxy-2-methyl-4-pyrone), an approved food additive in both Canada and the US. Potentially useful properties of BMOV include significant water solubility, neutral charge, and lipophilicity, a combination designed to enhance GI absorption, probably through a passive diffusion process. BMOV is effective in lowering blood glucose at a lower dose than VS and does not show evidence of toxicity over a 6-mo period of administration in streptozotocin-diabetic rats (13, 42) . Both oral gavage and intraperitoneal (ip) administrations indicate that BMOV is two to three times more potent than its parent compound, VS, in bringing about acute glucose lowering in this experimental model of insulindependent diabetes (41) .
Because BMOV displays favorable chemical and physiological properties, we were interested in its biodistribution after oral or ip administration. To this end, we prepared BMOV and VS, each containing 48 V as a tracer. 48 V has a half-life of 16 days and decays to nonradioactive 48 Ti by means of positron and gamma emission (␥ ϭ 511, 983, 1,312 KeV). 48 V was isolated as non-carrier-added 48 VS (43) ; the compounds used in these biodistribution studies were carrier-added 48 VS and 48 V-BMOV. Incorporation of 48 V into both BMOV and VS permitted direct comparison of the uptake and tissue distribution characteristics of these two compounds. Previous studies have looked at biodistributions after intratracheal, intragastric, or intravenous (iv) administration of 48 V-radiolabeled tracers over periods of several days to several weeks (21, 31, 40) . In our study, early time points were emphasized to elucidate the curve of uptake, and comparison of the two compounds over a period of 24 h permitted prediction of kinetic parameters in a variety of tissues.
To gain an integrated picture of whole body vanadium biolocalization, compartmental analysis of the tracer data was undertaken (5) . An existing compartmental model of vanadium metabolism (28) was used as a starting point for model construction by using simulation, analysis, and modeling (SAAM II) software (SAAM Institute, Seattle, WA) (4). O . Immediately before administration of the solution, the pH was adjusted to between 3.5 and 4 by dropwise addition of 1 M NaOH. The total volume was then increased to 12 ml with the addition of water.
MATERIALS AND METHODS
Carrier-added 48 V-BMOV in the initial oral and ip experiments (A and C) was synthesized as follows: to the mixture of 0.2 mmol (50 mg) of VOSO 4 ·3H 2 O and 3-4 eq of maltol was added an appropriate volume of 48 VS (in 0.01 M H 2 SO 4 ). With rapid stirring, 0.5 ml of 1 M NaOH was added dropwise to the suspension at 80°C. This temperature was maintained for another 10 min so that the reaction mixture was almost dry. 48 V-BMOV was isolated as a gray-green solid. Immediately before administration, it was dissolved in 16 ml of water.
In the preparation of 48 V-BMOV in the subsequent oral gavage administration (experiment B), 0.08 mmol (18 mg) of VOSO 4 ·3H 2 O and 4 eq of maltol were mixed in water. After dissolution of the solid, 0.8 ml of 0.2 M NaOH was added dropwise over a 10-min period. To this mixture was added an appropriate amount of 48 At each time point in all studies, three rats were anesthetized with halothane, blood was obtained from the carotid artery, and the anesthetized animals were then killed by cervical dislocation. Tissues were collected and placed in preweighed receptacles. Liver, kidney, muscle, spleen, lung, testicle, bone, heart, and brain samples were rinsed in normal saline, weighed, and blotted dry before freezing. In the second oral gavage study (experiment B), urine, fecal, stomach, and GI tissue samples were also collected. All tissue samples were stored frozen at Ϫ20°C until counted for 48 V activity. The activity was recorded in a well gamma counter (Canberra Packard, Cobra II, Auto-gamma/3-in. crystal). The percentage of administered dose (%AD) was calculated as a fraction of the ''standard counts'' for that time period, determined by counting the equivalent volume of radiolabeled solution with the same set of samples (Fig. 2 , as %AD/organ). In this carrier-added study, calculating %AD corrects for variation of two to three times in the amount of 48 V and even a small variation in the dose of cold vanadium. The total blood (7.8% of body wt), bone (12% of body wt), and muscle (45% of body wt) masses were calculated according to reported methods (24) .
Kinetic modeling. Simulation of 48 V uptake, distribution, and excretion was carried out by using SAAM II software (version 1.0.2) (4, 5). Data, in %AD/g tissue, from the initial oral gavage study (experiment A) were used to modify a model of vanadium metabolism published previously (28) . The fractional transfer coefficients (k ij ), where i and j are compartments, derived from experiment A were then used as a starting point for modeling the data from the second oral gavage study (experiment B) . Initial values were varied by iteration until a consistent set of parameters was obtained for each compound, with the greater variability of the second data set for each compound tested having been accounted for. Experiment C, with the highest overall coefficient of variation (CV; 0.9), was modeled last as an extension of the combined oral gavage studies, according to a previously established paradigm (37) . In accordance with standard modeling nomenclature (14) , k ij represents the fraction of material moving from compartment j to compartment i per unit time (h). Residence time is equivalent to the inverse of k ij for those compartments having only one egress; for blood, residence time is defined as 1/⌺k i1 , where compartment 1 represents blood (Fig. 3) (22) . Absorption of vanadium 24 h postadministration was calculated as (intake Ϫ fecal excretion) as a percentage of administered oral dose (22) .
RESULTS
Overall, for oral administration the highest concentrations of 48 V (expressed as %AD/g wet wt of tissue) were seen in kidney, followed by bone, blood, liver, http://jap.physiology.org/ spleen, and heart (see Fig. 2 for data as %AD/organ). 1 The concentrations in the above tissues did not exceed 0.6 %AD/g at any one time point (see below). In most other tissues, 48 V concentration did not exceed 0.1 %AD/g of oral dose. The concentration of 48 V in bone exceeded that of kidney at 24 h after oral gavage. CVs for experiment B were considerably higher than those for experiment A (average CVs of 0.3 and 0.5 for experiments A and B, respectively). Ip injection of 48 V-labeled compounds (experiment C) resulted in a higher apparent uptake in kidney and bone (not exceeding 1.6 %AD/g tissue), with little change in uptake for most other tissues between 4 and 24 h after injection, compared with either of the oral gavage experiments. 1 The relative concentrations of 48 V in bone and kidney by oral gavage, in %administered dose/organ or tissue [on the assumption that bone mass is 12% of body wt, muscle mass is 45% of body wt, and that these values, together with individual organ weights, were used to calculate total 48 V content from radioactivity (counts · min Ϫ1 · g tissue Ϫ1 ) in representative samples from each tissue]. Fig. 3 . Compartmental model of vanadium metabolism. Ovals are kinetically homogeneous and distinct compartments; nos., compartment nos. in mathematical model; arrows, transfer pathways; tissues, combination of soft organ tissues (heart, lung, brain, pancreas, and muscle). Sampling sites included in construction of model were liver, kidney, bone, and testes. Blood, urine, and fecal data were used to verify model. GI a and GI b , equivalent gastrointestinal compartments. http://jap.physiology.org/ after ip administration were also considerably higher than those after an oral dose (see below).
Soft tissue uptake from oral gavage of 48 VS and 48 V-BMOV, as %AD/organ (Fig. 2) , on the basis of average total tissue or organ weights, was greatest overall in liver Ͼ kidney Ͼ spleen Ͼ heart Ͼ testes Ͼ lung. The highest 48 V content at 24 h after oral gavage was seen in bone, liver, and kidney (Fig. 2) ; however, muscle also took up appreciable amounts of 48 V (Fig. 2) because of the high percentage of body weight (45%) represented by muscle.
A 13-compartment model (including urinary and fecal ''sinks'') adequately described the data for both 48 V-BMOV and 48 VS carrier-added doses by oral gavage (Fig. 3) . High variation in the data, both within data sets and between experiments A and B, precluded a more complex model (14) . Hence, the tissues represented (see Fig. 3 ) were chosen on the basis of previous studies showing uptake into these tissues (12) . Remaining tissues sampled (heart, brain, spleen, lung, pancreas, and muscle) were included in a ''lumped'' compartment, labeled as compartment 7. A kinetic heterogeneity in kidney was apparent, with the data fitting best to a two-compartment kidney. The three-compartment GI represents a delay between oral input and fecal output and does not signify physiological differences between these compartments (38) .
Compartmental analysis revealed a pattern of increased uptake from an oral dose of 48 V-BMOV compared with that of 48 VS. The greatest difference in uptake was seen in liver, which had a four times greater uptake of 48 V-BMOV relative to 48 VS. The schematic of the model (Fig. 3) shows oral input proceeding through a three-compartment GI, with absorbed 48 V taken up into the blood and from there being distributed to shortand long-stay tissues. Unabsorbed 48 V was excreted via the feces, whereas excretion of absorbed 48 V was via the urine through the second kidney compartment. Recirculation of 48 V is possible through both biliary secretion from the liver and resecretion back to blood from the second kidney compartment. Simulations of tracer disappearance by using the combined data sets, in %AD/g tissue, are presented in Fig. 4 ( 48 VS and 48 V-BMOV). Most tissues showed a gradual uptake, peaking at 2-6 h after gavage, with a decline thereafter; however, bone, liver, and kidney uptakes remained high at 24 h, indicating continued accumulation or slow clearance.
Apparent absorption of 48 V-BMOV was greater than that of 48 VS. The primary route of elimination was via the feces. On the basis of compartmental analysis of combined data sets (experiments A and B), 75% of 48 VS and 62% of 48 V-BMOV were excreted unabsorbed in the feces within 24 h after oral gavage. Although the time frame of this experiment was too short to accurately determine absorption, the model-predicted apparent vanadium absorption was 25% for 48 VS and 38% for 48 V-BMOV. These values are most likely a considerable overestimate of vanadium absorption because they are based on estimates from 24-h data sets only. The model-predicted absorption values were adequate to indicate a trend toward greater absorption of 48 V-BMOV compared with 48 VS, ϳ1.5 times greater.
The bone-to-kidney-to-liver ratios of 48 V concentrations (in %AD/g) 24 h after oral gavage predicted by the model were 0.3265:0.1163:0.082 for 48 V-BMOV and (Table 1) . Thus the proportions of 48 V taken up by bone, kidney, and liver after 48 V-BMOV treatment were ϳ3, 1.4, and 4 times, respectively, greater than those after 48 VS treatment. Averaging the increased uptake into liver, kidney, and bone resulted in a ratio of 48 V-BMOV to 48 VS uptake of 2.7. With total tissue weight accounted for, the principal uptakes of 48 V with use of an oral dose of BMOV vs. that of VS were 0.82 vs. 0.21% in liver, 0.23 vs. 0.17% in kidney, 1.14 vs. 0.67% in muscle, 3.55 vs. 2.73% in blood, and 8.62 vs. 2.99% in bone, on the basis of model-predicted compartmental masses at 24 h after gavage.
Residence times of 48 V (and the fractional transfer coefficients on which they were based) for the tissues modeled are given in Table 2 . The shortest residence times were in blood; the longest in bone. Residence times in blood were calculated to be 7 min for 48 V-BMOV and 5 min for 48 VS; in bone, residence times of 31 days for 48 V-BMOV and 11 days for 48 VS were calculated.
DISCUSSION
These results clearly demonstrate the increased tissue uptake from an oral dose of 48 V-BMOV compared with that of 48 VS. This is in accordance with comparisons in tissue uptake between iron sulfate and the iron maltol complex, tris(maltolato)iron(III) (2, 3, 23) . These studies have shown that, by forming a stable, neutral complex with Fe 3ϩ , maltol enhanced Fe 3ϩ absorption across the rat small intestine in vivo and that not only was the Fe 3ϩ held in soluble form but it was also efficiently carried into the mucosa. At the same time, regulatory processes to prevent Fe 3ϩ overload were not bypassed. In our study, complexation of labeled vanadium(IV) with maltol resulted in enhanced uptake and slower excretion of 48 V-BMOV compared with 48 VS (Fig.  4, Tables 1 and 2 ). Absorption was also greater with 48 V-BMOV than with 48 VS. This greater absorption and tissue uptake are also consistent with the increased pharmacological potency in lowering in vivo blood glucose levels seen previously (41) .
The long residence time of 48 V in bone (11.1 days with use of 48 VS and 31.3 days with use of 48 V-BMOV) predicted by our model is in agreement with earlier studies (1, 28) . Subcutaneous injection of rats with 48 V-VO 4 3Ϫ (1.8 mg V/kg) analyzed with a two-compartment model for each tissue (1) predicted a half-life for bone of 376 h (15.6 days), which would be equivalent to a residence time of 22.6 days (t 1/2 ϭln2RT, where RT is residence time). Prediction of a previous vanadium model (28) [assuming that the unspecified long-stay tissue in the model of Patterson et al. (28) represents bone] was Ͼ10 4 h, or ϳ42 days, also reasonably close to the residence times predicted by our model. Variability within data sets, and between the first and second oral gavage studies (experiments A and B), resulted in high error terms for the fractional transfer coefficients representing movement of vanadium between compartments and, as a consequence, also for calculated residence times.
In another study, at 24 h postinjection, %AD (of 48 V-vanadyl chloride added to ammonium metavanadate) was 1.25% in blood, 17.9% in bone, and 2.65% in muscle (1) 3Ϫ , VO 2ϩ , or BMOV is probably the cause of this low localization; however, the longer time frame is also a factor. Hamel and Duckworth (18) predicted longer residence times than we calculated for a variety of soft tissues (bone vanadium was not measured) in rats on the basis of patterns of uptake and redistribution of low levels of dietary vanadium, as detected by neutronactivation analysis over a longer time period. The significant difference in dose and the chronic, rather than acute, nature of the study may explain this discrepancy. The researchers (18) also observed that 2.7% of a gavage dose was in the blood (total) at 24 h, which is in good agreement with our calculations.
The kinetic heterogeneity in kidney predicted by our model suggests that the longer-stay kidney compartment may represent stored vanadium, whereas the short-stay kidney compartment may represent a vana- Percent administered dose (%AD; as %AD/g tissue) predicted by model (Fig. 3) at 24-h time point. Average %AD of 48 V-bis (maltolato)-oxovanadium(IV) (BMOV)/vanadyl sulfate-48 ( 48 VS) for liver, kidney, and bone was 2.7. 2 , kinetically distinct compartments that could be either physiologically or biochemically distinguishable, with no anatomic separation implied; numbers, compartment numbers in model (Fig. 3) . * RT 1 ϭ 1/͚k i,1 . †RT 2 ϭ1/͚k i, 13 . dium-excretion pathway. All studies to date indicate that kidney is a primary target of vanadium localization, along with liver and bone (6, 21, 31) .
The amounts of 48 V predicted to be excreted in the feces 24 h after an oral dose (75 and 62% for 48 VS and 48 V-BMOV, respectively) are in line with the amount measured by Bogden et al. (6) , in which 59% of an ingested dose of sodium metavanadate was recovered in the feces. Oral gavage of rats with 5 µmol 48 V-Na 3 VO 4 resulted in a 4-day recovery of 48 V, 69% in stool and 12.5% in urine (40) . The short time frame of this experiment (24 h) made a more accurate determination of absorption impossible. On the basis of other studies, actual absorption of orally administered vanadium is likely much lower (1-10%) (26) . The pattern of unexcreted 48 V in tissues was kidney Ͼ bone Ͼ liver Ͼ intestine Ͼ muscle (in %AD/g tissue) and was unchanged when administration was ip rather than gavage. This is in agreement with earlier studies (32, 40) , showing a similar pattern of tissue distribution after 48 V administration, whether oral, ip, or iv. The increase in label retention up to ϳ4 h seen in our studies was also apparent in a previous 48 V study in rats (21) , although because the latter study was via iv injection, much more 48 V was excreted in the urine than in the feces. The highest concentration of 48 V-VO 4 3Ϫ in blood was seen at 2 h postgavage in another study (1) .
In conclusion, these results showed the distribution of vanadium in different body tissues after oral or ip administration, with concentration in bone Ͼ kidney Ͼ liver Ͼ spleen Ͼ heart Ͼ testes Ͼ lung Ͼ pancreas Ͼ brain at 24 h. Compartmental modeling permitted detection of significant patterns in a particularly ''noisy'' data set and also allowed prediction of approximate residence times for key tissues. Tissue distribution patterns with use of 48 V-BMOV differed from those with use of 48 VS, with relatively higher 48 V liver-to-kidney ratio from the organovanadium complex. Results of this analysis emphasize the importance of early blood collection times to define the curve of vanadium disappearance from blood and, by contrast, a longer time frame to chart vanadium accumulation in bone more accurately. Tissue uptake after oral gavage of 48 V-BMOV was approximately two to three times higher than with 48 VS (Table 1) . This result was consistent with the increased acute glucose-lowering potency of two to three times seen with BMOV compared with VS (41) .
